Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
93 hedge funds and large institutions have $264M invested in Concert Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 16 closing their positions.
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
3% more funds holding
Funds holding: 90 → 93 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less capital invested
Capital invested by funds: $264M → $264M (-$871K)
67% less call options, than puts
Call options by funds: $37K | Put options by funds: $113K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$10.5M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$6.82M |
| 3 |
Renaissance Technologies
New York
|
+$4.1M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.91M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$6.33M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$6.04M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$4.63M |
| 4 |
Morgan Stanley
New York
|
-$4.17M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.37M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AL
101
Airain Ltd
St. Peter Port,
Guernsey
| – | -$415K | -22,126 | Closed |
|
|
SCA
102
Secor Capital Advisors
New York
| – | -$334K | -17,804 | Closed |
|
|
SKK
103
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| – | -$282K | -15,002 | Closed |
|
|
GAM
104
Gotham Asset Management
New York
| – | -$232K | -12,367 | Closed |
|
105
Goldman Sachs
New York
| – | -$219K | -11,679 | Closed |
|
|
DTL
106
Dynamic Technology Lab
Singapore
| – | -$212K | -11,312 | Closed |
|
|
PA
107
Perceptive Advisors
New York
| – | -$195K | -10,379 | Closed |
|
|
PAM
108
Panagora Asset Management
Boston,
Massachusetts
| – | -$58K | -3,088 | Closed |
|
109
BlackRock
New York
| – | -$8K | -400 | Closed |
|
CNCE Hedge Fund Activity: Q4 2015 in Review
93 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2015, worth a combined $264M — down 0.33% from $264M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CNCE positions and 16 closed out — a net gain of 3 holders — while 32 added to existing stakes and 29 trimmed.
The largest buyer was Numeric Investors, adding an estimated $10.5M. The largest seller was Jennison Associates, exiting entirely with an estimated $6.33M sold.
- 93 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2015, up from 90 in Q3 2015.
- Funds reported $264M of Concert Pharmaceuticals, Inc. stock for Q4 2015, down 0.33% quarter-over-quarter.
- 19 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2015 and 16 closed out, a net change of +3 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q4 2015 was Numeric Investors, an estimated $10.5M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q4 2015 was Jennison Associates, an estimated $6.33M sold.
Based on aggregated 13F filings for Q4 2015.